Could a daily sip of carbon monoxide help control Parkinson's?
Disease control
Not yet recruiting
This study is testing the safety and drug levels of HBI-002, a daily oral liquid containing a low dose of carbon monoxide (CO), in people with Parkinson's disease. Over 14 days, 36 participants will take either the drug or a placebo. The main goal is to see if the treatment is sa…
Phase: PHASE2 • Sponsor: Hillhurst Biopharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC